Our data are consistent with those obtained by studying human BRAFV600E mutant glioma cell lines, which point to re-activation of MAPK pathway and increased AKT and EGFR signaling activity as a mechanisms of adaptation and resistance to BRAFV600E inhibition (Supplementary Figure S3) [21, 46]. This evidence concerns the gene EGFR and glioma.